| ²é¿´: 808 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
ÈýÒ¶²ÝÍõÌú³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
Ó¢Ò뺺£¬Ð»Ð»
|
||
|
1.Transfections with has-miR-29a, -29b-1, -29c mimics and negative control (Ambion, Austin, TX, USA) were performed at a concentration of 100 nM with Lipofectamine 2000 (Invitrogen,Carlsbad, CA, USA). The expressions of DNMT1, DNMT3A and DNMT3B were knocked down stably in A549 and H1299 cell lines¡£using a lentiviral shRNA system from Santa Cruz Biotechnology (Dallas, Texas, USA) with puromycin selection. Transient knock down of WIF-1 was achieved by using WIF-1 shRNA Plasmid (Santa Cruz) according to the manufacturer¡¯s instructions. For the demethylation assay, 5-Aza-deoxycytidine (5-Aza, Sigma¨CAldrich, St. Louis, MO, USA) was added at a concentration of 10lM for 72 h 2 . Methylation-Specific PCR (MSP) Genomic DNA was extracted with the DNA Maxi Kit (Qiagen, Valencia, CA), and modified with sodium bisulfite using the MethylCode Bisulfite Conversion Kit (Invitrogen) according to the manufacturer¡¯s protocol. The methylation-specific or unmethylation-specific primer (MSP or USP) for WIF-1 was designed according to a previous report[7](Table 1). MiR-29s are transcribed into two primary transcripts from two chromosomes (miR-29b1and miR-29a at chromosome 7q32; miR-29b2 and miR-29c at chromosome 1q32). The MSP and USP were designed using the MethPrimer program (https://www.urogene.org/cgi-bin/methprimer/methprimer). Primers for miR-29b1 and miR-29a correspond to the promoter region sequences 1112 to1085 and993 to 971, respectively (Table 1). Primers for miR-29b2 and miR-29c correspond to the promoter region sequences 1339 to1314 and1178 to1153, respectively (Table 1). 3. Cell proliferation assays Cancer cells were transfected with microRNA mimics and/or WIF-1 shRNA. Seventy-two hours after transfection, cells wereseeded into 96-well plates (510 3 cells per well), and incubated at 37C. The number of viable cells was measured at daily intervals. A volume of 10lL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well and incubated for 4 h. The precipitate formed was dissolved by addition of 100lL of dimethyl sulfoxide and absorbance was measured at 562 nm using an ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA). Each experiment was performed in triplicate and repeated three times 4. Apoptosis assay Cells were seeded in 6-well plates at a density of 110 6 cells per well and transfected with microRNA mimics and/or WIF-1 shRNA. Seventy-two hours after transfection, the cells were resuspended and stained with FITC-conjugated anti-annexin V antibody and propidium iodide (PI) using the Annexin V-FITC Apoptosis Detection Kit (Sigma¨CAldrich). Stained cells were then quantified by FACSCalibur flow cytometry (Becton Dickinson, USA). 5. Statistical analysis Differences between two groups were assessed by the Student¡¯s t-test or Mann¨CWhitney¡¯s U-test. Correlations were assessed by Pearson¡¯s correlation test. Variance analysis between multiple groups was performed by one-way ANOVA. The data were presented as mean ¡À standard deviation (SD) andp< 0.05 was considered statistically significant |
» ²ÂÄãϲ»¶
¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÄÜÔ´²ÄÁÏ»¯Ñ§¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú8-10Ãû
ÒѾÓÐ12È˻ظ´
288Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ4È˻ظ´
ÕÐÊÕµ÷¼Á˶ʿ
ÒѾÓÐ10È˻ظ´
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶274Ò»Ö¾Ô¸ÉÂÎ÷ʦ·¶´óѧÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ4È˻ظ´
085601²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´

ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ÈýÒ¶²ÝÍõ: ½ð±Ò+25, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-08-28 09:57:43
ÈýÒ¶²ÝÍõ: ½ð±Ò+25, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-08-28 09:57:43
|
¸Õ²ÅÍüÁËɾµô²¿·ÖÔÎÄ£¬ÒÔÏÂÎÄΪ׼£º 1. ²ÉÓÃLipofectamine 2000 £¨Invitrogen,Carlsbad, CA, USA£©×ªÈ¾hsa-miR-29a¡¢ -29b-1¡¢-29c£¨Ä£ÄâÎÒÔ¼°ÒõÐÔ¶ÔÕÕ (Ambion, Austin, TX, USA) £¬Å¨¶ÈΪ100 nM¡£ÔÚA549ºÍH1299ϸ°ûÖÐÀûÓÃÂý²¡¶¾ÔØÌåshRNAϵͳ£¨º¬ÓÐàÑßÊÃ¹ËØÉ¸Ñ¡±ê¼Ç£©£¨Santa Cruz Biotechnology£¬Dallas, Texas, USA£©Îȶ¨×ªÈ¾·½·¨ÇüõDNMT1¡¢DNMT3AºÍDNMT3BµÄ±í´ï¡£¸ù¾ÝÉú²úÉÌ˵Ã÷ÊéÀûÓÃWIF-1 shRNA Plasmid (Santa Cruz)˲ʱÇüõWIF-1£¨µÄ±í´ï£©¡£È¥¼×»ù»¯ÊµÑéʱ£¬ÓÃ10 ¦ÌM 5-Aza £¨Sigma¨CAldrich, St. Louis, MO, USA) ´¦Àí72Сʱ¡£ 2 . ¼×»ù»¯ÌØÒìÐÔPCR (MSP) ÓÃDNA Maxi Kit(Qiagen, Valencia, CA)ÌáÈ¡»ùÒò×éDNA£¬²¢ÓÃMethylCode™ Bisulfite Conversion Kit £¨Invitrogen£©¸ù¾ÝÉú²úÉÌʹÓÃÊÖ²á½øÐÐÑÇÁòËáÇâÄÆ½øÐÐÐÞÊΡ£¸ù¾ÝÒÔǰµÄ±¨¸æ[7]Éè¼ÆWIF-1¼×»ù»¯ÌØÒìÐÔÒýÎïºÍ·Ç¼×»ù»¯ÌØÒìÒýÎMSP»òUSP£©(±í1)¡£MiR-29s´ÓÁ½¸ö²»Í¬È¾É«ÌåÉÏת¼³ÉÁ½¸öÖ÷Ҫת¼²úÎmiR-29b1ºÍmiR-29aÔÚȾɫÌå7q32; miR-29b2ºÍmiR-29cÔÚȾɫÌå1q32£©¡£MSPºÍUSPÓÃMethPrimer³ÌÐòÉè¼Æ (https://www.urogene.org/cgi-bin/methprimer/methprimer)¡£miR-29b1ÒýÎïºÍmiR-29aÒýÎï·Ö±ð¶ÔÓ¦ÓÚÆô¶¯×ÓÇøÓò˳Ðò1112µ½1085¡¢¼°993µ½971 (±í1)¡£miR-29b2ÒýÎïºÍmiR-29cÒýÎï·Ö±ð¶ÔÓ¦ÓÚÆô¶¯×Ó˳ÐòµÄ1339ÖÁ1314ºÍ1178ÖÁ1153(±í1)¡£ 3. ϸ°ûÔöֳʵÑé Ö×Áöϸ°ûתȾmicroRNAÄ£ÄâÎïºÍ/»òWIF-1 shRNA¡£×ªÈ¾ºó72Сʱ£¬Ï¸°ûÖÖÖ²ÓÚ96¿×°å£¨5000ϸ°û/¿×£©£¬²¢ÓÚ37¶ÈÅàÑø¡£Ã¿Ìì¼ÆÊý»îϸ°ûÊýÁ¿¡£Ã¿¿×¼ÓÈë10 ¦Ìl 5 mg/mlµÄMTT²¢¼ÌÐøÅàÑø4Сʱ¡£ËùÐγɵijÁµíÈÜÓÚ100 ¦Ìl¶ø¼ÒÑÇí¿£¬²¢ÓÃELISAø±êÒÇ (Bio-Rad Laboratories, Hercules, CA, USA)¼ì²â562 nmµÄ¹âÎüÊÕ¶È¡£Ã¿Ò»ÊµÑéÉèÈý¸öƽÐÐʵÑ飬ͬÑùµÄʵÑéÖØ¸´Èý´Î¡£ 4. µòÍö¼ì²â ϸ°ûÖÖÖ²ÓÚ6¿×°åÖУ¬ÃܶÈΪÿ¿×1°ÙÍòϸ°û£¬ÓÃmicroRNAÄ£ÄâÎïºÍ/»òWIF-1 shRNAתȾ¡£×ªÈ¾ºó72Сʱ£¬ÔÙ´ÎÐü¸¡Ï¸°û²¢ÓÃFITC½»ÁªµÄ¿¹Ä¤Áªµ°°×V¿¹ÌåºÍµâ»¯±ûण¨PI£©¶Ôϸ°ûȾɫ£¬È¾É«²ÉÓÃĤÁªµ°°×V-FITCµòÍö¼ì²âÊÔ¼ÁºÐ (Sigma¨CAldrich)½øÐС£ÓÃFACSCaliburÁ÷ʽϸ°ûÒÇ (Becton Dickinson, USA)¶ÔȾɫϸ°û½øÐж¨Á¿¡£ 5. ÓÃStudent¡¯s t¼ìÑé»òMann¨CWhitney¡¯s U¼ìÑé¶ÔÁ½×é¼äµÄ²îÒì½øÐÐͳ¼ÆÑ§·ÖÎö¡£ÓÃPearson¡¯sµÄÏà¹Ø¼ìÑé½øÐÐÏà¹Ø·ÖÎö¡£Í¨¹ýµ¥ÒòËØ·½²î·ÖÎö½øÐжà×é¼ä·½²î·ÖÎö¡£Êý¾ÝÓþùÊý¡À±ê×¼²î(SD)±íʾ£¬ÊÓp< 0.05ΪÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒå¡£ |
3Â¥2014-08-28 08:56:52
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
1. ²ÉÓÃLipofectamine 2000 £¨Invitrogen,Carlsbad, CA, USA£©×ªÈ¾hsa-miR-29a¡¢ -29b-1¡¢-29c£¨Ä£ÄâÎÒÔ¼°ÒõÐÔ¶ÔÕÕ (Ambion, Austin, TX, USA) £¬Å¨¶ÈΪ100 nM¡£ÔÚA549ºÍH1299ϸ°ûÖÐÀûÓÃÂý²¡¶¾ÔØÌåshRNAϵͳ£¨º¬ÓÐàÑßÊÃ¹ËØÉ¸Ñ¡±ê¼Ç£©£¨Santa Cruz Biotechnology£¬Dallas, Texas, USA£©Îȶ¨×ªÈ¾·½·¨ÇüõDNMT1¡¢DNMT3AºÍDNMT3BµÄ±í´ï¡£¸ù¾ÝÉú²úÉÌ˵Ã÷ÊéÀûÓÃWIF-1 shRNA Plasmid (Santa Cruz)˲ʱÇüõWIF-1£¨µÄ±í´ï£©¡£È¥¼×»ù»¯ÊµÑéʱ£¬ÓÃ10 ¦ÌM 5-Aza £¨Sigma¨CAldrich, St. Louis, MO, USA) ´¦Àí72Сʱ¡£ 2 . ¼×»ù»¯ÌØÒìÐÔPCR (MSP) ÓÃDNA Maxi Kit(Qiagen, Valencia, CA)ÌáÈ¡»ùÒò×éDNA£¬²¢ÓÃMethylCode™ Bisulfite Conversion Kit £¨Invitrogen£©¸ù¾ÝÉú²úÉÌʹÓÃÊÖ²á½øÐÐÑÇÁòËáÇâÄÆ½øÐÐÐÞÊΡ£¸ù¾ÝÒÔǰµÄ±¨¸æ[7]Éè¼ÆWIF-1¼×»ù»¯ÌØÒìÐÔÒýÎïºÍ·Ç¼×»ù»¯ÌØÒìÒýÎMSP»òUSP£©(±í1)¡£MiR-29s´ÓÁ½¸ö²»Í¬È¾É«ÌåÉÏת¼³ÉÁ½¸öÖ÷Ҫת¼²úÎmiR-29b1ºÍmiR-29aÔÚȾɫÌå7q32; miR-29b2ºÍmiR-29cÔÚȾɫÌå1q32£©¡£MSPºÍUSPÓÃMethPrimer³ÌÐòÉè¼Æ (https://www.urogene.org/cgi-bin/methprimer/methprimer)¡£ The MSP and USP were designed using the MethPrimer program (https://www.urogene.org/cgi-bin/methprimer/methprimer)¡£miR-29b1ÒýÎïºÍmiR-29aÒýÎï·Ö±ð¶ÔÓ¦ÓÚÆô¶¯×ÓÇøÓò˳Ðò1112µ½1085¡¢¼°993µ½971 (±í1)¡£miR-29b2ÒýÎïºÍmiR-29cÒýÎï·Ö±ð¶ÔÓ¦ÓÚÆô¶¯×Ó˳ÐòµÄ1339ÖÁ1314ºÍ1178ÖÁ1153(±í1)¡£ 3. ϸ°ûÔöֳʵÑé Ö×Áöϸ°ûתȾmicroRNAÄ£ÄâÎïºÍ/»òWIF-1 shRNA¡£×ªÈ¾ºó72Сʱ£¬Ï¸°ûÖÖÖ²ÓÚ96¿×°å£¨5000ϸ°û/¿×£©£¬²¢ÓÚ37¶ÈÅàÑø¡£Ã¿Ìì¼ÆÊý»îϸ°ûÊýÁ¿¡£Ã¿¿×¼ÓÈë10 ¦Ìl 5 mg/mlµÄMTT²¢¼ÌÐøÅàÑø4Сʱ¡£ËùÐγɵijÁµíÈÜÓÚ100 ¦Ìl¶ø¼ÒÑÇí¿£¬²¢ÓÃELISAø±êÒÇ (Bio-Rad Laboratories, Hercules, CA, USA)¼ì²â562 nmµÄ¹âÎüÊÕ¶È¡£Ã¿Ò»ÊµÑéÉèÈý¸öƽÐÐʵÑ飬ͬÑùµÄʵÑéÖØ¸´Èý´Î¡£ 4. µòÍö¼ì²â ϸ°ûÖÖÖ²ÓÚ6¿×°åÖУ¬ÃܶÈΪÿ¿×1°ÙÍòϸ°û£¬ÓÃmicroRNAÄ£ÄâÎïºÍ/»òWIF-1 shRNAתȾ¡£×ªÈ¾ºó72Сʱ£¬ÔÙ´ÎÐü¸¡Ï¸°û²¢ÓÃFITC½»ÁªµÄ¿¹Ä¤Áªµ°°×V¿¹ÌåºÍµâ»¯±ûण¨PI£©¶Ôϸ°ûȾɫ£¬È¾É«²ÉÓÃĤÁªµ°°×V-FITCµòÍö¼ì²âÊÔ¼ÁºÐ (Sigma¨CAldrich)½øÐС£ÓÃFACSCaliburÁ÷ʽϸ°ûÒÇ (Becton Dickinson, USA)¶ÔȾɫϸ°û½øÐж¨Á¿¡£ 5. ÓÃStudent¡¯s t¼ìÑé»òMann¨CWhitney¡¯s U¼ìÑé¶ÔÁ½×é¼äµÄ²îÒì½øÐÐͳ¼ÆÑ§·ÖÎö¡£ÓÃPearson¡¯sµÄÏà¹Ø¼ìÑé½øÐÐÏà¹Ø·ÖÎö¡£Í¨¹ýµ¥ÒòËØ·½²î·ÖÎö½øÐжà×é¼ä·½²î·ÖÎö¡£Êý¾ÝÓþùÊý¡À±ê×¼²î(SD)±íʾ£¬ÊÓp< 0.05ΪÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒå¡£ |
2Â¥2014-08-28 08:53:51













»Ø¸´´ËÂ¥